$ATOS News

Atossa Therapeutics Announces Acceptance Of (Z)-Endoxifen DMD Manuscript For Publication In Degenerative Neurological And Neuromuscular Disease

Atossa Therapeutics To Host Virtual KOL Event Focused On Evolving Clinical And Translational Data Supporting Development Of (Z)-Endoxifen As Potential Next-Gen Endocrine Therapy Backbone Across Multiple ER-Positive Breast Cancer Settings

Atossa Therapeutics Q1 EPS $(1.11) Misses $(0.94) Estimate

Atossa Therapeutics Announces FDA Rare Pediatric Disease Designation To (Z)-endoxifen For The Treatment Of McCune-Albright Syndrome In Females

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service

HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Q4 EPS $(0.03) Beats $(0.07) Estimate

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Atossa Therapeutics Presents Oral Clinical Update On (Z)-endoxifen At MDA Clinical & Scientific Conference

Atossa Therapeutics Files Prospectus For Offering $50M Common Shares

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Atossa Therapeutics Intends To Complete Enrollment In Combination Therapy Arms Of I-SPY 2 EOP In H2, EVANGELINE Trial By Mid-Year

We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Atossa Therapeutics Passes Five-Year Reauthorization Of Rare Pediatric Disease Priority Review Voucher Program

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending